遗传学
 （前言）

Dr. Cui Ke-Hui

​

Dr. Cui, Ke-Hui (崔可惠) was born on May 15, 1948, in Guangzhou, China, with ancestral roots in Taiping County, Anhui Province. Dr. Cui’s father, Mr. Cui, Shenzhi, was personally selected by President Ke Lin of Zhongshan Medical College to serve as the college's director of library, while his mother, Dr. Chen, Zijian, was a senior lecturer in Department of Obstetrics and Gynecology at Zhongshan Medical College. Dr. Cui has two older brothers and one younger sister.​ In 1955, Dr. Cui enrolled in Guangzhou Shuqianlu Primary School and entered Guangzhou No. 16 Middle School in 1961. From 1968 to 1973, he worked as a rubber tapper at Xiqing Farm in Danzhou County, Hainan Island, where he gained profound insights into society and life.

​

In November 1973, Dr. Cui began studying medical laboratory technology at the Nursing and Technical Program of Zhongshan Medical College. During this period, he participated in the development of the nation’s first dose-reduced long-acting oral contraceptive performed by Professor Zhuang Guanglun at First Affiliated Hospital of Zhongshan Medical University. Dr. Cui translated English procedures into Chinese for estrogen and progesterone extraction.​ In 1976, Dr. Cui independently established the oral mucosal exfoliated cell sex chromatin (Barr's body) examination experiment and pioneered the use of amniotic fluid exfoliated cells for fetal sex determination, achieving an accuracy rate of 86%. Subsequently, he established China's first amniotic fluid chromosome genetics laboratory and introduced G-banding karyotyping technology in the laboratory.  

​

In 1977, Dr. Cui passed the first national college entrance examination following the Cultural Revolution and re-entered Zhongshan Medical College to further deepen his medical knowledge. During university, he and President Peng Wenwei jointly established the nation’s first All-English medical program, promoting the internationalization of medical education.​ After graduating in December 1982, Dr. Cui worked as a resident doctor in the Department of Obstetrics and Gynecology at the First Affiliated Hospital of Zhongshan Medical University, where he was also responsible for teaching and research in the Department of Obstetrics and Gynecology. This experience laid a solid clinical foundation for his future research in reproductive medicine.

​

​In 1986, Dr. Cui came to the University of Florida in the United States as a visiting scholar to study in vitro fertilization techniques, molecular biology, and pharmacological research. In 1989, he moved to Australia to reunite with his wife and eldest daughter. Later, they had a second daughter. In 1996, he and his family relocated to the United States again through the U.S. State Department's "O" visa program and settled in Chicago.

​

Dr. Cui is not only a Doctor of Medicine (M.D.) but also holds a Doctor of Philosophy (Ph.D.) degree. He is certified as a High-Complexity Clinical Laboratory Director (HCLD) and Embryology Laboratory Director (ELD) by the American Association of Bioanalysts. Dr. Cui has extensive experience and remarkable achievements in reproductive medicine, in vitro fertilization (IVF), preimplantation genetic diagnosis (PGD), tissue cloning, and embryonic stem cell research. His research spans cutting-edge areas of embryology, ranging from mice and marmosets to humans, and he has played a pivotal role in advancing global PGD technologies. During his Ph.D. studies (1989-1993) at The Queen Elizabeth Hospital (TQEH, the third IVF center in the world) of the University of Adelaide in Australia, he was mentored by Professors Colin Matthews and Bob Seamark. In 1993, Dr. Ke-Hui Cui published groundbreaking research in Nature on the size differences between human X and Y sperm, demonstrating that X sperm are significantly larger than Y sperm. This was the first global confirmation of such a difference, as the experiments showed that only Y sperm contained the testis-determining gene on the Y chromosome. This discovery provided new perspectives for reproductive medicine and genetics, driving deeper understanding of sperm characteristics and their roles in fertilization.

​

As early as 1991, Dr. Cui established Australia’s first preimplantation genetic diagnoses (PGD) center at TQEH at the University of Adelaide, where he successfully carried out the country's first PGD baby without cystic fibrosis. This achievement made Australia the first nation in the world to utilize PGD rather than PGT (preimplantation genetic testing) technology. Among his published works, Dr. Cui highlighted the difference between PGD and PGT: First: PGD employs specific genes and sequences with specially designed primers; Second, ensuring no allele dropout and Third, 100% diagnostic accuracy in foundational experiments with single cells. "D" in PGD means "Diagnoses", while "T" in PGT means "Testing" which lacks the same level of precision. In contrast, PGT uses nonspecific sequences located in introns, which may result in misdiagnosis and allele dropout. For Dr. Cui's outstanding contributions to PGD, particularly in sex determination of mouse embryos and PGD for cystic fibrosis, he was awarded the Marion Merrell Dow Prize twice (in 1991 and 1994) in the world meeting organized by the Fertility Society of Australia. (This prestigious award, established by the U.S.-based pharmaceutical company Marion Merrell Dow, recognizes researchers who have made exceptional achievements in medicine and pharmacology). Furthermore, Dr. Cui serves as a peer reviewer for several international journals, including the Journal of Assisted Reproduction and Genetics, and Human Reproduction, earning widespread recognition and respect within the scientific community. He also serviced as a reviewer of licensing body, Human Fertilisation and Embryology Authority (HFEA) of the United Kingdom.

​

​

​

​

​

​

​

​